EXAMS · SÃO PAULO
Breast and ovarian cancer genetic panel: who it is for, sample collection and cost
A test that analyzes several genes at once to look for inherited changes that increase the risk of breast and ovarian cancer.

Understand the exam
Most breast and ovarian cancers are not inherited: changes in the BRCA1 and BRCA2 genes account for 5% to 10% of breast cancer cases and 15% of ovarian cancer cases. Some cases, however, occur because a person was born with a change in a gene linked to cancer risk, and this change can be inherited from either the mother or the father.
BRCA1 and BRCA2 are the most widely known genes, but other genes can also cause hereditary ovarian cancer.
The result may be positive (a harmful gene change), negative (no harmful change found) or show a variant of uncertain significance. A variant of uncertain significance means it is not yet known whether that change increases risk, and it should not change management on its own.
How it is done
The test uses a sample containing your DNA, which may be blood, saliva or cells scraped from the inside of your cheek. The team provides instructions about the sample type and preparation when you schedule.
The sample is sent to a laboratory, where specialists look for changes in the DNA.
When it is recommended
- Newly diagnosed breast cancer at age 65 or younger: guidelines recommend offering BRCA1 and BRCA2 gene testing
- Epithelial ovarian cancer at any age
- Breast cancer in a man: a reason to consider BRCA1 and BRCA2 gene testing
- Relatives with ovarian cancer, male breast cancer, pancreatic cancer, or metastatic or high-risk prostate cancer: a reason to consider BRCA1 and BRCA2 gene testing
- A relative with an identified harmful inherited change in the BRCA1 or BRCA2 gene: a reason to consider testing these genes
- Recurrent breast cancer in someone eligible for PARP inhibitor medications: guidelines recommend offering BRCA1 and BRCA2 gene testing
Does the exam hurt?
If the sample is blood, you may feel a small prick when the needle goes in or comes out, and mild pain at the site usually goes away quickly.
After the exam
Cost and health plans
| Exam | Self-pay | Duration | Health plans |
|---|---|---|---|
| 42-gene breast and ovarian cancer genetic panel | From R$ 2,880.00 (≈ US$ 503, estimated) | Confirm with the team | Ask the team about coverage |
The team confirms the requested option, coverage, and conditions before booking.
Book an examFrequently asked questions
Does a positive result mean I will get cancer?
No. A positive result shows a higher risk, but it does not say whether or when the person will get cancer. Based on it, the doctor may recommend more intensive screening and, in some cases, medications or surgeries to reduce the risk.
What is a variant of uncertain significance?
It is a change in a gene for which there is not yet enough information to know whether it increases cancer risk. It should not change care on its own, and the person should receive follow-up because the variant may be reclassified in the future.
What is the difference between this panel and a BRCA-only test?
The BRCA test looks only at the BRCA1 and BRCA2 genes. The panel evaluates several genes at once, increasing the chance of finding changes in genes other than BRCA.
Can men have the panel?
Yes. Men also inherit and pass on these changes, and some of them increase the risk of male breast cancer and prostate cancer.
Do I need to fast or do any preparation?
No preparation is specified on this page for this test. The team provides guidance when you schedule.
How long do results take?
The team explains the turnaround time when assisting you.
Does my health plan cover the breast and ovarian genetic panel?
Check the table on this page for plans with listed coverage; if yours is not shown, the team will confirm coverage for you. The self-pay price is in the pricing table on this page.
Where we see patients
References
- PDQ Cancer Genetics Editorial Board. Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version. National Cancer Institute. 2025.
- National Cancer Institute (NCI). BRCA Gene Changes: Cancer Risk and Genetic Testing. NCI. 2024.
- Konstantinopoulos PA, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020.
- US Preventive Services Task Force; Owens DK, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019.
- National Library of Medicine. Breast cancer. MedlinePlus Genetics. 2021.
- Bedrosian I, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol. 2024.
- National Library of Medicine. BRCA Genetic Test. MedlinePlus. 2025.
- National Library of Medicine. How is genetic testing done? MedlinePlus Genetics. 2021.
This content is informational and does not replace a consultation.
Updated on